Evidence map›Paper›PMID 39907897›Full record

ReviewAdvances in therapy2025

Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.

Piotr Wiland, Charlotte Both, Norman B Gaylis, Russell D Cohen, Jonas Halfvarson, Lena Lemke, Oliver von Richter, Andrew Blauvelt

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Piotr WilandDepartment of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland.
Charlotte BothHEXAL AG (a Sandoz Company), Holzkirchen, Germany.
Norman B GaylisArthritis and Rheumatic Disease Specialties, Aventura, FL, USA.
Russell D CohenDepartment of Medicine, Section of Gastroenterology, University of Chicago, Chicago, IL, USA.
Jonas HalfvarsonDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID 0000-0003-0122-7234
Lena LemkeHEXAL AG (a Sandoz Company), Holzkirchen, Germany.
Oliver von RichterHEXAL AG (a Sandoz Company), Holzkirchen, Germany.
Andrew BlauveltOregon Medical Research Center, Portland, OR, USA. blauveltconsults@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sandoz-adalimumab (SDZ-ADL; Hyrimoz

Indexed as

AdalimumabBiosimilar PharmaceuticalsDrug SubstitutionHumansRandomized Controlled Trials as TopicTreatment OutcomeAdalimumabBiosimilar PharmaceuticalsAdalimumabArthritisBiosimilarGP2017HyrimozInflammatory bowel diseasePsoriasisSandoz-adalimumabSpondyloarthritis

Identifiers

PMID39907897
PMCPMC11949999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.